Clinical Trial Update: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating nivolumab and combination therapy in virus-associated tumors has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Various Advanced Cancer

Drugs mentioned

• Nivolumab in combination therapy (nivolumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Various Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-12